Why the study?
Prior retrospective and non-randomized studies showed QRSarea strongly associates with CRT response, but its strength for patient selection had not been evaluated in a randomized trial.
Does CRT-D reduce the combination of all-cause mortality and heart failure hospitalization compared to ICD in heart failure patients, and is this benefit predicted by QRSarea?
Does CRT-D reduce the combination of all-cause mortality and heart failure hospitalization compared to ICD in heart failure patients, and is this benefit predicted by QRSarea?
QRSarea provides a consistent, objective estimation of CRT benefit in heart failure patients, with greater benefit observed in patients with larger QRSarea.
QRSarea may identify CRT responders for ACM/HFH reduction; leaves open prospective validation before guiding selection.
Background Prior retrospective and non-randomized studies indicate that the area under the QRS complex (QRSarea) has a strong association with the response to cardiac resynchronisation therapy (CRT). Purpose To evaluate the strength of QRSarea for selection of patients for CRT using a subanalysis of the RAFT trial, in which heart failure patients were randomized to CRT-D or ICD. Methods RAFT (Resynchronization–Defibrillation for Ambulatory Heart Failure Trial) was a multicenter, double-blind, randomized, controlled study that included patients with heart failure symptoms (NYHA II-III), ejection fraction <30% and QRS duration >120 ms. Data from 1081 patients with sufficient ECG quality was available for QRSarea analysis. Primary endpoint was the combination of all-cause mortality (ACM) and hospitalization for heart failure (HFH). Subgroups were created using QRS duration (QRSd; < and >/= 150 ms), left bundle branch block (LBBB; Y/N) and QRSarea (quartiles). QRSarea was determined from the vectorcardiogram, synthesized from digitized 12-lead ECGs as the sum of the area under the QRS complex in the X, Y and Z leads. CRT benefit was defined as a significant difference in outcome between the CRTD and the ICD group. Results The RAFT QRSarea cohort consisted of 68% patients with ischemic cardiomyopathy (ICM) and 77% patients with LBBB. The highest two QRSarea quartiles consisted for > 90% of patients with LBBB as well as ~50% patients with non-ICM. In contrast, the lower two quartiles consisted of ~50% with LBBB and >80% patients with ICM. Larger QRSarea was also associated with lower age and LVEF as well as hypertension. A significant relation existed between QRSarea and CRT benefit regarding the primary endpoint (HR 0.80 (95% CI 0.69-0.94)), the CRT benefit regarding the primary endpoint being significant in the two higher QRSarea quartiles (figure; dashed =ICD, drawn lines = CRT). CRT patients in all QRSarea quartiles benefited regarding ACM while benefit in HFH occurred only in patients in the upper two quartiles. Conclusions This randomized study demonstrates that QRSarea provides a consistent estimation of the benefit of CRT in patients with heart failure, presumably because QRSarea reflects both electrophysiological and non-electrophysiological factors and can be determined objectively, accurately and in terms of continuous values.
No takes yet. Share an insight, caveat, or question.
Prinzen et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: